AZN vs. HALO: AstraZeneca vs. Halozyme Therapeutics Stock Comparison

Company Profile

AstraZeneca (AZN) and Halozyme Therapeutics (HALO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while HALO is classified in Biotechnology.

Halozyme Therapeutics (HALO) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; AstraZeneca (AZN) at 22.57% also sits in the top quartile.

Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and AstraZeneca (AZN) at 17.68% also retains a top-quartile share.

Both AstraZeneca (AZN) at 29.57% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both AstraZeneca (AZN) at 8.63% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both AstraZeneca (AZN) at 45.33% and Halozyme Therapeutics (HALO) at -25.36% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while AstraZeneca (AZN) at 1.01 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AZN.

Only one side’s leverage can be read here: AstraZeneca (AZN) carries debt-to-equity ratio of 0.66 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both AstraZeneca (AZN) at 26.37 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both AstraZeneca (AZN) at 4.63 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile AstraZeneca (AZN) reports 5.59, ranking against industry peers normally.

Valuation Metrics